Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum.

Habler, Katharina; Kalla, Anne-Sophie; Rychlik, Michael; Vogeser, Michael; Teupser, Daniel

Habler, Katharina; Kalla, Anne-Sophie; Rychlik, Michael; Vogeser, Michael; Teupser, Daniel.

Afiliação

Habler K; Institute of Laboratory Medicine, University Hospital, LMU Munich, Germany. Electronic address: katharina.habler@med.uni-muenchen.de.
Kalla AS; Institute of Laboratory Medicine, University Hospital, LMU Munich, Germany; Chair of Analytical Food Chemistry, Technical University of Munich, Germany.
Rychlik M; Chair of Analytical Food Chemistry, Technical University of Munich, Germany.
Vogeser M; Institute of Laboratory Medicine, University Hospital, LMU Munich, Germany.
Teupser D; Institute of Laboratory Medicine, University Hospital, LMU Munich, Germany.

J Pharm Biomed Anal ; 225: 115211, 2023 Feb 20.

Article em En | MEDLINE | ID: mdl-36603395

Assuntos

Neoplasias da Mama; Feminino; Humanos; Aminopiridinas/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Cromatografia Líquida; Quinase 4 Dependente de Ciclina/antagonistas & inibidores; Monitoramento de Medicamentos; Inibidores de Proteínas Quinases; Espectrometria de Massas em Tandem/métodos; Quinase 6 Dependente de Ciclina/antagonistas & inibidores

Palavras-chave

Abemaciclib; CDK4/6 inhibitor; LCMS/; MS; Palbociclib; Ribociclib; Therapeutic drug monitoring

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Guideline Limite: Female / Humans Idioma: En Revista: J Pharm Biomed Anal Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google